Literature DB >> 32859636

Expression Patterns of CD44 and AREG Under Treatment With Selective Tyrosine Kinase Inhibitors in HPV+ and HPV- Squamous Cell Carcinoma.

Benjamin Kansy1, Christoph Aderhold2, Lena Huber2, Sonja Ludwig2, Richard Birk2,3, Anne Lammert2, Stephan Lang4, Nicole Rotter2, Benedikt Kramer2.   

Abstract

BACKGROUND: We investigated the expression patterns of cluster of differentiation (CD) 44 and amphiregulin (AREG), two signaling molecules essential for cell proliferation and differentiation, under the influence of selective tyrosine kinase inhibitors (TKIs) in human papillomavirus (HPV)+ and HPV- squamous carcinoma cell lines.
MATERIALS AND METHODS: The protein expression of CD44 and AREG was determined by sandwich enzyme-linked immunosorbent assay in HPV- cell lines UMSCC-11A and UMSCC-14C, and HPV+ CERV-196 cells after TKI treatment.
RESULTS: The expression of AREG and CD44 was dependent on the cell line's HPV status. AREG expression increased after incubation with nilotinib in HPV+ tumor cells. The expression of CD44 was significantly influenced by all drugs; its expression under selective epidermal growth factor receptor inhibition was mostly reduced, whereas nilotinib led to an exceptional increase of CD44 expression.
CONCLUSION: The selective drug treatment options significantly influenced the expression of CD44 and AREG in HPV- and HPV+ tumor cells, constituting the need for personalized treatment options. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  AREG; CD44; afatinib; dasatinib; drug resistance; erlotinib; gefitinib; head and neck squamous cell carcinoma; nilotinib

Mesh:

Substances:

Year:  2020        PMID: 32859636      PMCID: PMC7472457          DOI: 10.21873/cgp.20214

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  47 in total

1.  Differential recruitment of CD44 isoforms by ErbB ligands reveals an involvement of CD44 in breast cancer.

Authors:  Iris Morath; Christian Jung; Romain Lévêque; Chen Linfeng; Robert-Alain Toillon; Arne Warth; Véronique Orian-Rousseau
Journal:  Oncogene       Date:  2018-01-11       Impact factor: 9.867

Review 2.  Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck.

Authors:  Mark E Sharafinski; Robert L Ferris; Soldano Ferrone; Jennifer R Grandis
Journal:  Head Neck       Date:  2010-10       Impact factor: 3.147

3.  Expression of the ERBB Family of Ligands and Receptors in Gastric Cancer.

Authors:  Sun-Ju Byeon; Hye Seung Lee; Min-A Kim; Byung Lan Lee; Woo Ho Kim
Journal:  Pathobiology       Date:  2017-04-12       Impact factor: 4.342

4.  Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program.

Authors:  I Posner; M Engel; A Gazit; A Levitzki
Journal:  Mol Pharmacol       Date:  1994-04       Impact factor: 4.436

Review 5.  Amphiregulin.

Authors:  Carmen Berasain; Matías A Avila
Journal:  Semin Cell Dev Biol       Date:  2014-01-23       Impact factor: 7.727

6.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.

Authors:  James Bean; Cameron Brennan; Jin-Yuan Shih; Gregory Riely; Agnes Viale; Lu Wang; Dhananjay Chitale; Noriko Motoi; Janos Szoke; Stephen Broderick; Marissa Balak; Wen-Cheng Chang; Chong-Jen Yu; Adi Gazdar; Harvey Pass; Valerie Rusch; William Gerald; Shiu-Feng Huang; Pan-Chyr Yang; Vincent Miller; Marc Ladanyi; Chih-Hsin Yang; William Pao
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-18       Impact factor: 11.205

7.  Human Papillomavirus-Associated Cancers - United States, 2008-2012.

Authors:  Laura J Viens; S Jane Henley; Meg Watson; Lauri E Markowitz; Cheryll C Thomas; Trevor D Thompson; Hilda Razzaghi; Mona Saraiya
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-07-08       Impact factor: 17.586

8.  EGFR kinase promotes acquisition of stem cell-like properties: a potential therapeutic target in head and neck squamous cell carcinoma stem cells.

Authors:  Eric L Abhold; Alan Kiang; Elham Rahimy; Selena Z Kuo; Jessica Wang-Rodriguez; Jay Patrick Lopez; Katherine J Blair; Michael Andrew Yu; Martin Haas; Kevin T Brumund; Xabier Altuna; Andrew Patel; Robert A Weisman; Weg M Ongkeko
Journal:  PLoS One       Date:  2012-02-27       Impact factor: 3.240

9.  Trends in Human Papillomavirus-Associated Cancers - United States, 1999-2015.

Authors:  Elizabeth A Van Dyne; S Jane Henley; Mona Saraiya; Cheryll C Thomas; Lauri E Markowitz; Vicki B Benard
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-08-24       Impact factor: 17.586

10.  Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging.

Authors:  Brooke N McKnight; Nerissa T Viola-Villegas
Journal:  Breast Cancer Res       Date:  2018-10-25       Impact factor: 6.466

View more
  1 in total

1.  Single-Cell Transcriptome Analysis Reveals Different Immune Signatures in HPV- and HPV + Driven Human Head and Neck Squamous Cell Carcinoma.

Authors:  Simin Li; Yang Wang; Rui Sun; Debora Franceschi; Hongying Pan; Chenxuan Wei; Anthony Chukwunonso Ogbuehi; Bernd Lethaus; Vuk Savkovic; Sebastian Gaus; Rüdiger Zimmerer; Dirk Ziebolz; Gerhard Schmalz; Xiao Jiang
Journal:  J Immunol Res       Date:  2022-09-16       Impact factor: 4.493

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.